Trial Profile

A phase II/III adaptive Clinical Trial for Pirfenidone in oncology-related pulmonary complications

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 May 2025 According to Gyre Therapeutics media release, the company plans to begin this adaptive Phase 2/3 trial in the second half of 2025 across top oncology centers in China.
03 Apr 2025 New trial record
31 Mar 2025 According to Gyre Therapeutics media release, company announced that the National Medical Products Administration (NMPA) of the People Republic of China (PRC) has approved its clinical trial application for a potential new indication for pirfenidone in oncology-related pulmonary complications.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com